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Abstract
Multidrug membrane transporters (efflux pumps) can selectively extrude a variety of structurally
and functionally diverse substrates (e.g., chemotoxics, antibiotics), leading to multidrug resistance
(MDR) and ineffective treatment of a wide variety of diseases. In this study, we have designed and
constructed fusion gene (egfp-mexB) of N-terminal mexB with C-terminal egfp, inserted it into a
plasmid vector (pMMB67EH), and successfully expressed it in ΔMexB (MexB deletion) strain of
Pseudomonas aeruginosa to create a new strain that expresses MexA-(EGFP-MexB)-OprM. We
characterized the fusion gene using gel electrophoresis and DNA sequencing, and determined their
expression in live cells by measuring the fluorescence of EGFP in single live cells using
fluorescence microscopy. Efflux function of the new strain was studied by measuring its
accumulation kinetics of ethidium bromide (EtBr, a pump substrate) using fluorescence
spectroscopy, which was compared with the cells (WT, ΔMexM, ΔABM, and nalB1) with various
expression levels of MexAB-OprM. The new strain shows 6-fold lower accumulation rates of
EtBr (15 μM) than ΔABM, 4-fold lower than ΔMexB, but only 1.1-fold higher than WT. As EtBr
concentration increases to 40 μM, the new strain has nearly the same accumulation rate of EtBr as
ΔMexB, but 1.4-fold higher than WT. We observed the nearly same level of inhibitory effect of
CCCP (carbonyl cyanide-m-chlorophenylhydrazone) on the efflux of EtBr by the new strain and
WT. Antibiotic susceptibility study shows that the minimum inhibitory concentrations (MICs) of
aztreonam (AZT) and chloramphenicol (CP) for the new strain are 6-fold or 3-fold lower than
WT, respectively, and 2-fold higher than those of ΔMexB. Taken together, the results suggest that
the fusion protein partially retains the efflux function of MexAB-OprM. Modeled structure of the
fusion protein shows that the position and orientation of the N-terminal fused EGFP domain may
either partially block the translocation pore or restrict the movement of the individual pump
domains, which leads to partially restrict efflux activity.
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Introduction
Multidrug membrane transporters (efflux pumps) can selectively extrude a wide range of
substrates, which leads to multidrug resistance (MDR).1-2 These transporters exist in both
prokaryotes and eukaryotes.3-4 Pseudomonas (P.) aeruginosa (a ubiquitous gram-negative
bacterium) is a major opportunistic human pathogen and the leading cause of nosocomial
infections in cancer, transplant, burn, and cystic fibrosis patients.5-7 Its efflux pumps can
selectively extrude a wide variety of structurally and functionally diverse substrates, causing
MDR. MDR is the primary cause of ineffective therapeutic treatments toward the infections,
and the use of high doses of therapeutic agents that leads to severe side effects.
P. aeruginosa possesses several multidrug membrane transporters, including MexAB-OprM,
that belongs to the resistance-nodulation-cell division (RND) family.2, 7-10 The MexAB-
OprM is the primary membrane transporter in WT of P. aeruginosa. This tripartite drug
efflux pump consists of two inner membrane proteins (MexA and MexB) and one outer
membrane protein (OprM).11-13 This efflux pump extrudes a wide spectrum of structurally
and functionally unrelated antibiotics (e.g., AZT, CP, tetracycline, and gentamicin) using the
drive-force generated by proton gradients across the cellular membrane.14-15 The interplay
between the MexAB-OprM efflux system and the outer membrane barrier plays an
important role in MDR. 8, 16-17 In general, studies suggest that the transmembrane protein
(MexB) specifically recognizes and captures its substrates either from the lipid bilayer of
inner membrane or from cytoplasmic space, then transports them to the extracellular
medium through OprM which forms a channel in the outer membrane.18 The cooperation
between MexB and OprM is coordinated by the periplasmic membrane protein MexA.19-22
However, despite extensive studies, molecular mechanisms of multidrug membrane
transporters remain not yet fully understood.6, 23 Therefore, direct visualization and study of
MexB and its interaction with the pump substrates in live cells can shed new light on the
roles of MexB in efflux function of MexAB-OprM.
Fluorescent proteins (e.g., GFP) have been widely used as reporter genes and non-invasive
fluorescence probes to study molecular mechanisms and functions of proteins in live
cells.24-26 Fluorescent proteins fused with membrane transporters have been used to
determine the locations and topologies of ABC transporters.27-28 Our previous studies have
showed that fusion of BmrA (ABC transporter) with EGFP retains its efflux function.29-30
However, other studies have shown that proteins (membrane transporters) fused with GFP
may alter their functions.31-32 Notably, the effects of fusion of EGFP with tripartite efflux
pumps (e.g., MexAB-OprM) on their efflux function have not yet been reported. Thus, it is
crucial to first determine whether the MexA-(EGFP-MexB)-OprM retains the efflux
function of MexAB-OprM, before we use the fusion protein to study the efflux mechanisms
of MexAB-OprM.
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Current methods for study of multidrug membrane transporters in bacterial and mammalian
cells include the measurement of their accumulation of radioactively labeled substrates (14C
and 3H) and the fluorescence dyes (e.g., EtBr).29-30, 33-36 Fluorescent dyes (EtBr) emit weak
fluorescence in aqueous solution (outside cells) and become strongly fluorescent in non-
polar and hydrophobic environments, especially as they enter the cells and intercalate with
DNA.37 Thus, time-dependent (time-course) fluorescence intensity of EtBr is particularly
suitable for real-time monitoring of efflux kinetics of multidrug membrane transporters in
live cells. 29-30, 33-36, 38 Minimum inhibitory concentrations (MICs) of antibiotics that are
specific substrates of the transporters and show the specific susceptibility toward given
strains of bacterial cells have also been used to study efflux function of multidrug membrane
transporters.39
In this study, we fused C-terminus of egfp with N-terminus of mexB to construct egfp-mexB
fusion gene, and expressed it in MexB deleted strain of P. aeruginosa (ΔMexB) to create a
new strain, MexA-(EGFP-MexB)-OprM. We characterized the effects of fusion EGFP on
efflux function of MexAB-OprM by studying real-time accumulation of EtBr inside the
cells, inhibitory effects of the proton ionophore (CCCP) on intracellular EtBr accumulation,
and MICs of two representative antibiotics (AZT and CP) toward the cells. We used model
structural analysis to further determine the potential effects of fusion EGFP on the efflux
function of MexAB-OprM.
Experimental Section
Reagents and Cell Strains
PCR polymerase (Agilent Technologies), plasmid isolation kit (Qiagen), DNA gel extraction
kit (Qiagen), DNA ligation kit (Roche) which includes ligation enzyme (T4 DNA ligase)
and ligation buffer, SalI/HindIII (NEB), CP (Calbiochem), IPTG (GBT), CCCP (≥ 97%,
Sigma), carbenecillin (Sigma), AZT (Sigma), EtBr (Invitrogen), and E. coli DH5α
(Invitrogen) were purchased and used as received. P. aeruginosa strains (WT, nalB1,
ΔMexB, ΔABM) and plasmid (pMMB67EH) were provided by Hiroshi Yoneyama.40-41 All
other reagents except indicated were purchased from Sigma and used as received. The
nanopure deionized (DI) water (18 MΩ water, Barnstead) was used to prepare all solutions,
including the L-broth (LB) medium (1% tryptone, 0.5% yeast extract and 0.5% NaCl in DI
water, pH = 7.2).
Construction of egfp-mexB Fusion Gene and MexA-(EGFP-MexB)-OprM Strain
We fused N-terminal mexB gene with C-terminal egfp to prepare the egfp-mexB fusion gene
by asymmetrical PCR amplification, and then inserted it into the vector (pMMB67EH) to
prepare pMMB67EH-EGFP-MexB vector, as described in Figure S1 in online
supplementary information.42 We first used one pair of egfp primers (egfp primer-1: 5′-
CTTGTCGACAAGGGGATCCACCATGGTGAGCAAGG-3′ and egfp primer-2: 5′-
CAATGAAAAACTTCGACATCTTGTACAGCTCGTCCATGC-3′), and EGFP plasmid as
a template to amply egfp gene (Figure S1A-I). We then used only egfp primer-1 and the
amplified double-strand (ds) egfp gene as the template to create the coding strand of egfp
gene (single-strand, ss-egfp) (Figure S1A-II). Using the similar approaches, we used one
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pair of mexB primers (mexB primer-1: 5′-
GCATGGACGAGCTGTACAAGATGTCGAAGTTTTTCATTG-3′, mexB primer-2: 5′-
GATAAGCTTATCATTGCCCCTTTTCGAC-3′), and genomic DNA of P. aeruginosa as
the template to generate and amplify the mexB gene (Figure S1B-I). We used mexB primer-2
and the amplified ds-mexB gene as the template to generate and amplify the template strand
of mexB gene (ss-mexB) (Figure S1B-II), which has 20 bases that are complimentary to the
ss-egfp at the 3′-end. By mixing the ss-egfp with ss-mexB, it creates 20 base-pair (bp) ds-
DNA, that links the ss-egfp with ss-mexB, which is used as the template to generate and
amplify egfp-mexB fusion gene using both egfp primer-1 and mexB primer-2 as primers
(Figure S1AB-III). The PCR product of the egfp-mexB fusion gene was characterized by
agarose gel electrophoresis (0.8%, E = 8-10 V/cm), and purified by the gel purification kit.
The purified PCR products of egfp-mexB gene and vector (pMMB67EH) were digested by a
pair of restriction enzymes (SalI/HindIII), which were carried out by incubating the PCR
products (10 ng) or the vector (5 ng) with two units of SalI/HindIII each in the presence of
10x digestion buffer (4 or 3 μL) in DI water (40 or 30 μL) at 37 °C for 3 h, respectively
(Figure S1AB-IV). The digested products were characterized by the agarose gel
electrophoresis and purified via the gel extraction kit. After purification, the digested and
purified egfp-mexB gene and the vector (pMMB67EH) were ligated to produce
pMMB67EH-EGFP-MexB (Figure S1C). The ligation was carried out by incubating
digested and purified egfp-mexB fusion gene (20 nM) with digested and purified vector (5
nM) in the presence of one unit of T4 DNA ligase and 10× ligation buffer (2 μL) in DI water
(20 μL) at 12°C overnight. The digestion, gel electrophoresis and ligation were carried out
using the reported protocols.43
The pMMB67EH-EGFP-MexB was then transformed into DH5α competent cells
(Invitrogen) using heat shock. Briefly, we mixed the pMMB67EH-EGFP-MexB (10 μL, 0.1
μg/μL) with the competent cell suspension (100 μL, 2×107 cells/mL), placed the mixture on
ice for 30 min, followed by a heat shock at 42 °C for 90 s, then placed it back onto the ice
for another 2 min. We then added the LB medium (1 mL) to the mixture, incubated it in a
shaker (LabLine Orbit-Environ, 37°C, 200 rpm) for 1 h, and centrifuged the solution at 5000
rpm for 5 min. We removed the supernatant and suspended the pellets (transformed cells) in
the fresh medium, inoculated them onto LB agar plates (0.5% yeast extract, 0.5% NaCl, 1%
tryptone,1.5% agar and 100 μg/ml ampicillin), and incubated the plates at 37°C for 24 h.
Positive ligations were verified by restriction enzyme digestion (SalI/HindIII), PCR
amplification using the primers (egfp primer-1 and mexB primer-2), and DNA sequencing
(Applied Biosystem, 3730xl DNA Analyzer).
Plasmids with the correct sequence were finally transformed into MexB deletion strain
(ΔMexB) using electroporation.44-45 Briefly, the cells (ΔMexB) were cultured in the LB
medium in the shaker (200 rpm, 37 °C) until they reach the early log phase (optical density
at 600 nm, OD600nm = 0.3-0.5). The cells were then harvested using centrifugation (7000 g,
10 min, 4 °C), and washed with the sucrose (300 mM) three times, and resuspended in the
sucrose. The cell suspension was placed on ice for 30 min. We then mixed the cells (80 μL)
with the fusion plasmid (pMMB67EH-EGFP-MexB, 10 μL, 1 μg/μL), transferred them to a
pre-chilled sterile electroporation cuvette (gap between two electrodes = 0.2 cm), and
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applied the electric pulse (2.5 kV, 25 μF, 5 ms, one pulse) (Biorad Gene Pulser). The cells
were then cultured in the LB medium (3 mL) in the shaker (200 rpm, 37 °C) for 2 h, and
harvested using centrifugation (5000 rpm, 5 min). The cells were streaked onto the LB agar
plate containing 100 μg/ml carbenecillin, which was then incubated at 37 °C for 24 h. The
clones were picked and cultured at 37 °C in the LB medium with 100 μg/mL carbenecillin to
produce EGFP fused cells, MexA-(EGFP-MexB)-OprM.
Cell Culture and Assays
We pre-cultured each of five strains of P. aeruginosa: WT, nalB1, ΔMexB, ΔABM, and
MexA-(EGFP-MexB)-OprM, by inoculating a single clone of each strain from the LB agar
plate into the LB medium and placed them in the shaker (37 °C, 200 rpm) for 12 h. We then
cultured the cells in the fresh LB medium in the shaker (37 °C, 200 rpm) for another 8 h,
except adding 2 mM IPTG and 100 μg/mL carbenecillin in the medium for the culture of
MexA-(EGFP-MexB)-OprM cells to induce the expression of the fusion protein as the
OD600 nm of the cell suspension reached 0.5. We harvested the cells using centrifugation
(Beckman J2-21, JA-14 rotor, 6000 rpm, 23 °C, 10 min), washed them with the PBS buffer
(50 mM phosphate, 100 mM NaCl, pH 7.0) three times, and re-suspended them in the
buffer. The cell concentration in the buffer (OD600 nm = 0.1) was used to characterize the
expression of the fusion protein (EGFP-MexB) in single live cells using fluorescence
microscopy and to study the efflux function of membrane transporters by measuring
accumulation kinetics of EtBr in the cells using fluorescence spectroscopy.
Characterization of Expression of MexA-(EGFP-MexB)-OprM in Single Live Cells
The cells suspended in the PBS buffer were imaged in a micro-chamber using dark-field
optical microscopy and epi-fluorescence microscopy (Nikon, E-400) equipped with a CCD
camera (Micromax, Roper Scientific). The design and construction of the micro-chamber
and dark-field optical microscopy for imaging of single live cells were fully described in our
previous studies.33, 35, 38, 46 In this study, the fluorescence filter cube (Chroma Tech)
containing a band-pass excitation filter (455 ± 30 nm), band-pass emission filter (525 ± 30
nm) and a dichroic mirror (500 nm), was used for fluorescence imaging of expression of
EGFP-MexB in single live cells. The dark-field optical microscope is equipped with a dark-
field condenser (Oil 1.43-1.20, Nikon) and a 100x objective (Nikon Plan fluor 100× oil, iris,
SL. N.A. 0.5-1.3, W.D. 0.20 mm).
Fluorescence Spectroscopic Study of Efflux Function of MexA-(EGFP-MexB)-OprM in Live
Cells
Fluorescence intensity of EtBr (15 and 40 μM) incubated with the cells (OD 600 nm = 0.1) in
the PBS buffer in the presence or absence of CCCP (0.1 mM) was acquired over time (1-2
h) with 3s time interval at room temperature using a fluorescence spectrometer (Perkin-
Elmer, LS50B). The excitation and emission wavelengths were selected at 465 and 600 nm
with a width of each excitation and emission slit at 10 nm, respectively.
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Study of Minimum Inhibitory Concentration (MIC) of Antibiotics to the Cells
We measured the MICs of two representative antibiotics (AZT and CP) toward the cells:
WT, MexA-(EGFP-MexB)-OprM, ΔMexB, ΔABM, and nalB1. Each strain was pre-cultured
by inoculating a single clone from the LB agar plate into the LB medium (with 100 μg/mL
carbenecillin for the EGFP fusion strain to maintain the plasmid) in the shaker (200 rpm,
37°C) overnight. The cell suspension for each strain (100 μl, ∼104 cells) was added into the
refresh LB medium (2.9 mL) in the presence of dilution series of AZT (0-100 or 250 μg/mL)
or CP (0-100 or 250 μg/mL) with 100 μg/mL carbenecillin and 2 mM IPTG for the fusion
strain to induce the expression of fusion protein, in the shaker (200 rpm, 37°C) for another
16 h. The concentration and number of the cells in each cell cultured suspension were then
measured using the UV-vis spectroscopy (OD600 nm) and dark-field optical microscopy,
respectively.
Results and Discussion
Construction and Characterization of egfp-mexB Fusion Gene and its Expression
To directly visualize MexB and determine its roles in the efflux function of MexAB-OprM
using fluorescence microscopy and spectroscopy, we designed and constructed a new strain
of P. aeruginosa with MexB fused with EGFP (MexA-EGFP-MexB-OprM). We first
designed and constructed the egfp-mexB fusion gene as shown in Figure 1 and as described
in Methods (Figure S1). The amplified egfp-mexB gene and vector (pMMB67EH) were
digested and ligated to produce fusion plasmid (pMMB67EH-EGFP-MexB) (Figure S1).
We characterized the fusion gene (egfp-mexB) using DNA sequencing (Figure S2 in on-
supplementary information), and gel electrophoresis (Figure 2A). Note that PCR amplified
egfp-mexB, mexB and egfp genes contain 3888, 3171 and 756 bp, respectively, and the
fusion gene (egfp-mexB) was formed by overlapping (hybridizing) of the 39 bp of amplified
mexB and egfp genes (20 bp each), which leads to 3888 bp, instead of 3927 bp. The results
in Figure 2A show that the egfp-mexB gene (∼3880 bp in L2) includes mexB gene (∼3100
bp in L3), and egfp gene (∼750 bp in L4), indicating that the fusion gene (egfp-mexB) has
been successfully constructed. We also characterized the fusion plasmid (pMMB67EH-
EGFP-MexB) using DNA sequencing and gel electrophoresis (Figure 2B). The digested
fusion plasmid shows two bands, the original plasmid (pMMB67EH, 8.8 kb) and the fusion
gene (egfp-mexB, ∼3880 bp), which demonstrate that the fusion gene has been successfully
inserted into the original plasmid and the fusion plasmid (pMMB67EH-EGFP-MexB) has
been successfully constructed. The DNA sequences of both fusion gene and fusion plasmid
show that the sequences of mexB are in excellent agreement with those reported
previously.47
We transformed the characterized fusion plasmid (pMMB67EH-EGFP-MexB) into MexB
deletion strain (ΔMexB) and characterized their expression in single live cells by measuring
fluorescence of EGFP in single live cells using fluorescence microscopy and spectroscopy.
The results in Figure 3 show that all MexA-(EGFP-MexB)-OprM cells emit green
fluorescence, while other strains of P. aeruginosa, WT (MexAB-OprM), nalB1 (over
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expression of MexAB-OprM), ΔABM (deletion of MexAB-OprM), and ΔMexB (deletion of
MexB), do not.
Fluorescence Study of Efflux Function of MexA-(EGFP-MexB)-OprM in Live Cells
To determine whether EGFP-MexB protein expressed in ΔMexB cells maintains the efflux
function of MexAB-OprM and whether EGFP interfere the efflux function of the
transporter, we studied the efflux kinetics of EtBr by MexAB-OprM in live cells in real time
by measuring accumulation rates of intracellular EtBr using fluorescence spectroscopy. It is
worth noting that EtBr emits week fluorescence in aqueous solution (outside the cells), and
its fluorescence intensity increases substantially (up to 10-fold) as they enter into the cells
and intercalate with DNA.37 Therefore, EtBr has been used to monitor and characterize the
efflux kinetics of membrane transporters in live cells in real time.33, 35-36, 38, 40
Time-dependent fluorescence intensity of EtBr (15 and 40 μM) incubated with the live cells
(ΔABM, ΔMexB, MexA-EGFP-MexB-OprM, WT, and nalB-1) in PBS buffer show that
fluorescence intensity of EtBr increases with time and the rates highly depend upon the
expression level of MexAB-OprM in the cells (Figure 4). The highest rates and highest
fluorescence intensity at each given time were observed for EtBr incubated with the ΔABM
cells (Figure 4a), while the lowest rates and lowest fluorescence intensity were found for
nalB-1 cells with over-expression of MexAB-OprM (Figure 4e). The results show that the
MexAB-OprM extrudes the EtBr out of the cells, which leads to the lowest accumulation of
EtBr in nalB1. The results also demonstrate that we can use the accumulation rates of EtBr
in the cells to characterize the efflux function of MexAB-OprM.
The highest accumulation rate and highest fluorescence intensity of EtBr in the ΔABM cells
are followed by those of ΔMexB (Figure 4b), MexA-(EGFP-MexB)-OprM (Figure 4c), WT
(Figure 4d), and nalB1 cells (Figure 4e). Interestingly, the rates of MexA-(EGFP-MexB)-
OprM are only 1.1-fold higher than those of WT (nearly the same as WT), but 4-fold lower
than ΔMexB in the presence of 15 μM EtBr (Figure 4A). The results suggest that the fusion
strain extrudes the intracellular EtBr out of the cells nearly as effectively as WT cells, and it
is much more effectively than ΔMexB.
As concentration of EtBr increases from 15 μM (Figure 4A) to 40 μM (Figure 4B), the
accumulation rates of EtBr in MexA-(EGFP-MexB)-OprM increase and they are nearly the
same as ΔMexB, but 1.4-fold higher than WT, showing that the ineffectiveness of efflux
function of fusion pump is magnified upon the over-flowing (higher concentration) of
intracellular EtBr. The results (Figure 4) suggest that the fused EGFP may create steric
effect upon the efflux function of MexB, and hence the fusion pump (MexA-EGFP-MexB-
OprM) cannot extrude the substrate as effectively as WT (MexAB-OprM). The results in
Figure 4 further demonstrate that EGFP is fused with MexB, and MexA-(EGFP-MexB)-
OprM is expressed. Should EGFP be cleaved from MexB, we would have observed the
same efflux function of the fusion strain as that of WT.
Ding et al. Page 7






















Study of Inhibitory Effect of CCCP upon Efflux Function of MexA-(EGFP-MexB)-OprM in
Live Cells
We further characterized the efflux function of fusion pump by study of inhibitory effect of
CCCP upon the efflux function of the pump (Figure 5). Note that the CCCP can effectively
decrease the proton gradients across the cellular membrane, remove the energy source of the
transporters and hence disable the efflux function of the proton-motive transporters. The
results (Figure 5) show that the fluorescence intensity of intracellular EtBr increases with
time much more rapidly in the presence of CCCP than in the absence of CCCP, indicating
the inhibitory effect of CCCP upon the efflux functions of the transporters, and the
accumulation rates of intracellular EtBr by the cells are much more rapidly in the presence
of CCCP than its absence. Among five strains, the CCCP affects the efflux function of WT
most (Figure 5A), closely followed by fusion strain (MexA-EGFP-MexB-OprM) (Figure
5B), then ΔMexB (Figure 5C), ΔABM (Figure 5D), and nalB1 (Figure 5E). The lowest
effect of CCCP upon the efflux function of nalB1 could be attributed to the insufficient dose
of CCCP to disable over-expression of nalB1. Interestingly, the CCCP also affects the
accumulation rates of EtBr by ΔABM, which could be attributed to the presence of other
proton-motive transporters (e.g., MexCD-OprJ, MexEF-OprN) in ΔABM.48-49
Taken together, the results show that the fusion transporter (MexA-EGFP-MexB-OprM)
retains significant level of efflux function of MexAB-OprM. The fusion pump displays
similar efflux kinetics to WT in response to the lower dose of EtBr (Figure 4A), suggesting
that the fusion strain may be suitable for the study of efflux function of the transporter in
low dose substrates. Nonetheless, fusion of EGFP with MexB may create steric effects upon
its folding and/or interactions with MexA, OprM or pump substrates, and affect the efflux
function of MexAB-OprM (Figure 4B).
Antibiotic Susceptibility Study of Efflux Function of MexA-(EGFP-MexB)-OprM
To further investigate the efflux function of the fusion pump (MexA-EGFP-MexB-OprM),
we determined the susceptibility of all five strains of P. aeruginosa (WT, ΔMexB, MexA-
EGFP-MexB-OprM, ΔABM, and nalB1) toward two representative antibiotics (AZT and
CP). The results (Table 1) show that MIC of AZT for WT (3.13 μg/mL) is about 5-fold
lower than nalB1 (15.7 μg/mL), and 16-fold higher than ΔABM (0.2 μg/mL). The MIC of
CP for WT (25 μg/mL) is 4-fold lower than nalB1 (100 μg/mL), and 16-fold higher than
ΔABM (1.56 μg/mL). The results in Table 1 show that MICs of AZT and CP for each strain
highly depend upon the expression level of MexAB-OprM and they are the effective and
reliable parameters to characterize the efflux function of the transporter.
The results in Table 1 show that MIC of AZT for fusion strain (0.5 μg/mL) is about 6-fold
lower than WT (3.13 μg/mL), and 2-fold higher than ΔMexB (0.25 μg/mL). The MIC of CP
for fusion strain (8 μg/mL) is about 3-fold lower than WT (25 μg/mL), and 2-fold higher
than ΔMexB (4 μg/mL). The results further demonstrate the expression of fusion transporter
(MexA-EGFP-MexB-OprM). Should EGFP be cleaved from MexB, we would have
observed the same MICs for the fusion strain as that of WT. The results also further affirm
our hypothesis that the expression of EGFP-MexB in ΔMexB partially restores the efflux
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function of MexAB-OprM, and fusion of EGFP with MexB may affect the efflux function of
the transporter.
Structural Modeling and Analysis of MexA-(EGFP-MexB)-OprM Transporter
To understand how fusion of C-terminal EGFP with N-terminal MexB could create steric
effects upon efflux function of MexAB-OprM, we constructed secondary structure of
MexAB-OprM model based on the coordinates of the data-driven docking model of the
multidrug efflux pump (AcrA-AcrB-TolC) from P. aeruginosa (Figure 6A).50 We then
fused the EGFP domains to the N-termini of MexB in its trimeric assemblage (Figure 6B)
Initial coordinates of the complete trimeric pump were obtained from the data-driven
docking of AcrA-TolC onto AcrB.50 The individual components of the tripartite multidrug
efflux pump from P. aeruginosa are highly homologous to the corresponding components in
the MexAB-OprM transporter with up to 69% sequence identity between the antiporter
AcrB and MexB.51
Three dimensional structure alignment shows low average root-mean-square deviations
(RMSDs) for coordinate displacements of 2.053 Å for AcrA/MexA (PDB codes: 2F1M and
1VF7), 2.355 Å for AcrB/MexB (PDB codes: 2J8S and 2V50) and 2.064 Å for TolC/OprM
(PDB codes: 2VDD and 1WP1).52-53 The working model was assembled by secondary
structure matching of MexB on AcrB in its trimeric configuration.53-54 The EGFP model
was assembled separately using SWISS-MODEL,55 based on 3D structure of the GFP (PDB
code: 3OGO) with a sequence identity of 98.7%. The prediction of secondary structures
shows the linker region connecting the C-terminus of the EGFP domain to the N-terminus of
MexB to be unstructured.56 The connecting residues were built manually using program
Coot.54 The EGFP domains were positioned in the cytoplasmic space with no clashes to the
MexB domains and the membrane region. The structural models (Figure 6) were generated
using PyMOL.57
The structural model shows the location of the MexB N-termini at the cytosolic end of the
translocation pore of the transporter with the unstructured loop of the N-termini pointing
inward towards the trimeric pore (Figure 6A). Spatial placement of the EGFP domains in the
cytosol is limited by potential EGFP to EGFP, or EGFP to MexB clashes in the trimeric
configuration. The model structure shows that the position and orientation of the N-terminal
fused EGFP domains may either partially block the translocation pore or restrict the
movement of the individual pump domains, thereby partially restricting efflux activity
(Figure 6B).
Summary
In summary, we have designed and constructed the fusion gene (egfp-mexB), inserted it into
the plasmid vector (pMMB67EH) and successfully expressed it in ΔMexB strain of P.
aeruginosa. This approach allows us to create the new strain of P. aeruginosa that expresses
MexA-(EGFP-MexB)-OprM. We characterized the efflux function of the new strain by
measuring their accumulation kinetics of intracellular EtBr (a pump substrate), inhibitory
effects of CCCP upon its efflux function, and MICs of two representative antibiotics (AZT
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and CP). We compared these results with the cells with various expression levels of
MexAB-OprM (WT, ΔABM, ΔMexB, and nalB1), and found that the new strain shows 4-
fold lower accumulation rates of EtBr (15 μM) than ΔMexB (deletion of MexB), but only
1.1-fold higher than WT (nearly the same as WT). As EtBr concentration increases to 40
μM, the new strain has nearly the same accumulation rate of EtBr as ΔMexB, but 1.4-fold
higher than WT. Interestingly, the CCCP creates nearly the same level of inhibitory effects
upon the efflux function of the new strain as the WT, which are 2-3 times higher than their
effects upon ΔMexB and ΔABM. Antibiotic susceptibility study shows that the fusion strain
has 6-fold lower MIC of AZT and 3-folder lower MIC of CP than WT, and only 2-fold
higher than ΔMexB. Taken together, these results suggest that the fusion protein, MexA-
(EGFP-MexB)-OprM, partially retains the efflux function of MexAB-OprM. Modeled
structural study of the fusion pump shows that the position and orientation of the N-terminal
fused EGFP domains may either partially block the translocation pore or restrict the
movement of the individual pump domains, which lead to partially restrict efflux activity.
The work is in progress to characterize topologies and translocation mechanisms of fusion
pump and develop new approaches to generate the labeled MexB without affecting their
efflux functions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Design and construction of egfp-mexB fusion gene and their primers. Two egfp primers are
used to amply the egfp gene marked in red using EGFP plasmid as a template. Two mexB
primers are used to amply the mexB gene marked in green using the ds-mexB as a template.
Hexanucleotides of egfp P1 and mexB P2 labeled by bold and blue are SalI and HindIII sties,
respectively. These two primers are used to amply egfp-mexB fusion gene. The AAGGGGAT
region labeled by pink and italic corresponds to Shine-Dalgarno (SD) sequence of the mexB
gene. Underlined ATGs are initiation codons of egfp and mexB genes. CAT of egfp P2
primer as marked by bold and underlined is a complement triplet of the mexB initiation
codon (ATG). TCA of mexB P2 labeled by bold and underlined is a complement triplet of
the mexB termination codon (TGA). The detailed experimental design is described in Figure
S1 in on-line supplementary information.
Ding et al. Page 13






















egfp P1 egfp gen egfp P2 mexB P1 mexBgene mexB P2 









·• ..... , _.,/ 
··· ... 
··· .... _ ..... -··· 






·-....•.... , _.,.. 
····--... _.,······ _./ Hind lll 
CAAGGGGATCCACCt.TI2- (EGFP)- AAGt.TI2-(mexB)-TGATA 
egfp-mexB fus ion gene 
5'-CTTGTCGACAAGGGGATCCACCATGGTGAGCAAGG-3' 
5' -CAA T GAAAAACTTCGACATCTTG TACAGCTCGTCCATGC-3' 
5'-GCATGGACGAGCTGTACAAGATGTCGAAGTTTTTCATTG-3' 
5'-GAT AAGCTTATCA TTGCCCCTTTTCGAC-3' 
Figure 2.
Characterization of egfp-mexB fusion gene using agarose gel electrophoresis: (A): (L1)
DNA markers/ladders in base pair (bp); (L2) The egfp-mexB fusion gene amplified using
both egfp P1 and mexB P2 as primers (Figure S1A-B:III); (L3) The ds-mexB gene amplified
using the genomic DNA of P. aeruginosa as a template, and mexB P1 and P2 as primers
(Figure S1B-I); (L4) The ds-egfp gene amplified using the plasmid (pEGFP) as a template
and egfp P1 and P2 as primers. Arrows point to the PCR products of 750, 3100 and 3880 bp,
which agree well with the number of base pairs of egfp, mexB and egfp-mexB fusion gene.
The sequence of egfp-mexB is characterized using DNA sequencer and shown in Figure S2
in on-line supplementary information. (B): (L1) DNA markers/ladders in bp; (L2) The
pMMB67EH-EGFP-MexB vector digested by a pair of restriction enzymes, SalI/HindIII.
Arrows point to the digested vector plasmids at 8800 bp and egfp-mexB fusion gene at 3880
bp.
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Characterization of expression of egfp-mexB fusion gene in single live cells. (A) Dark-field
optical images and (B) green fluorescence images of single live cells: (a) MexA-(EGFP-
MexB)-OprM; (b) ΔMexB; (c) WT; (d) nalB1; and (e) ΔABM, show green fluorescence of
EGFP in (a) MexA-(EGFP-MexB)-OprM cells only, which indicates the expression of egfp-
mexB fusion gene in the cells. Scale bar = 5 μm.
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Figure 4.
Study of the dependence of accumulation and efflux kinetics of the intracellular EtBr on the
expression of MexAB-OprM and MexA-(EGFP-MexB)-OprM transporters in live cells.
Time-dependent fluorescence intensity of EtBr: (A) 15 and (B) 40 μM, incubated with the
cells (OD600 nm = 0.1 in PBS buffer, pH 7.2): (a) ΔABM, (b) ΔMexB, (c) MexA-(EGFP-
MexB)-OprM, (d) WT, and (e) nalB1 strains.
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Figure 5.
Study of inhibitory effects of CCCP (0.1 mM) on efflux function of MexAB-OprM and
MexA-(EGFP-MexB)-OprM transporters in live cells. Time-dependent fluorescence
intensity of EtBr (15 μM) incubated with the cells (OD600 nm = 0.1 in PBS buffer, pH 7.2):
(A) WT; (B) MexA-(EGFP-MexB)-OprM; (C) ΔMexB; (D) ΔABM; and (E) nalB1 strains,
in (a) the presence and (b) absence of CCCP.
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Figure 6.
The modeled structures of MexA-(EGFP-MexB)-OprM expressed in the cells (ΔMexB): (A)
Secondary structure of MexAB-OprM model is constructed based on the coordinates of the
data-driven docking model of the multidrug efflux pump (AcrA-AcrB-TolC) from P.
aeruginosa. The model shows the location of the MexB N-termini at the cytosolic end of the
translocation pore of the transporter with the unstructured loop of the N-termini pointing
inward towards the trimeric pore. (B) The EGFP domains were fused to the N-termini of
MexB in its trimer assemblage: (a) stereo side view and (b) bottom view of the structures.
Spatial placement of the EGFP domains in the cytosol is limited by potential EGFP to
EGFP, or EGFP to MexB clashes in the trimeric configuration. The position and orientation
of the N-terminal fused EGFP domains may either partially block the translocation pore or
restrict the movement of the individual pump domains, thereby restricting efflux activity.
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Table I
Study of Minimum Inhibitory Concentration (MIC) of Antibiotics, Aztreonam (AZT) and




WT (PAO4290: normal expression of MexAB-OprM) 3.13 25
MexA-(EGFP-MexB)-OprM (N-terminus of MexB fused with EGFP) 0.5 8
ΔMexB (TNP071: deletion of MexB, derivation of PAO4290) 0.25 4
ΔABM (TNP076: deletion of MexAB-OprM, derivative of PAO4290) 0.2 1.56
nalB1 (TNP030#1: a mutant that over-expression of MexAB-OprM) 15.7 100
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